CLINICAL_TRIALS
trial_result
· 2021-06-18
Clinical Trial Update: A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis [Phase 3]
Summary
Phase 3 long-term extension study of ixekizumab in axial spondyloarthritis completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Axial Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-18